Head-to-head comparison
Andrew Meds vs Signos
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Andrew Meds prices both molecules openly and says which 44 states can be treated by questionnaire alone — then routes every Get Started button on its semaglutide page to a different, cheaper program.
From $199/mo sema · From $299/mo tirz · Verified September 2026
Marked down on: Every Get Started button on the compounded semaglutide page opens a microdosing program at $99 a month, and that word appears nowhere else on the site.
Desk Score
Signos (Signos+) is a metabolic-health platform that bundles clinician-prescribed compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor (CGM) and app.
$199/mo (6-month prepay) sema · From $199/mo (lowest dose rung) tirz · Verified July 2026
Marked down on: Compounded GLP-1s are not FDA-approved finished products
Andrew Meds takes this head-to-head with the higher Desk Score, 79/100 (C+) against 62/100 (C) for Signos. Signos still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Andrew Meds
79/100
C+
Signos
62/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Andrew Meds | Signos |
|---|---|---|
| Semaglutide | From $199/moFrom $199/mo (compounded) | $199/mo6-month prepay$199/mo (6-month plan, compounded) |
| Tirzepatide | From $299/moFrom $299/mo (compounded) | From $199/molowest dose rung$199/mo (starting dose, compounded) |
| Coverage | All 50 states and D.C. (44 by questionnaire, the rest by live visit) | Not listed on Signos's site (checked July 2026) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Anyone who will confirm which program the checkout actually opened before paying for it. | Pairing compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor and app. |
| Desk Score | 79/100C+ | 62/100C |
The verdict
Desk pick — Andrew MedsAndrew Meds takes this head-to-head with the higher Desk Score, 79/100 (C+) against 62/100 (C) for Signos. Signos still holds its ground where its strengths line up with yours.
Choose Andrew Meds if…
Anyone who will confirm which program the checkout actually opened before paying for it.
From $199/mo sema · From $299/mo tirz · All 50 states and D.C. (44 by questionnaire, the rest by live visit)
Choose Signos if…
Pairing compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor and app.
$199/mo (6-month prepay) sema · From $199/mo (lowest dose rung) tirz
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Andrew Meds · Signos.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- Andrew Meds vs CoreAge Rx
- CoreAge Rx vs Signos
- Andrew Meds vs HealthRX
- HealthRX vs Signos
- Andrew Meds vs Breeze Meds
- Breeze Meds vs Signos
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.